Altadill Tatiana, Espadaler-Mazo Jordi, Liong Min-Tze
AB-Biotics SA, Sant Cugat del Vallès, 08172 Barcelona, Spain.
Department of Bioprocess Technology, School of Industrial Technology, University Sains Malaysia, Penang 11800, Malaysia.
Microorganisms. 2021 Mar 4;9(3):528. doi: 10.3390/microorganisms9030528.
We previously reported on the effects of DR7 on reducing Upper Respiratory Tract Infections (URTI) symptoms' score and frequency in 109 adults upon a 12-week consumption at 10 colony-forming units (CFU)/day, but several limitations were detected in the publication. Thus, the present study re-analyzed some data with the aim to address some of these weaknesses, and presents new data on duration of URTI and consumption of URTI-associated medication, as compared to the placebo. Our re-analyses found probiotic administration significantly reduced the proportion of patient days of URTI and of fever (all < 0.05). Recent history of URTI was a prevalent co-factor in affecting duration of URTI symptoms and fever, while other demographic and clinical factors had no influence. Exploratory analyses suggested probiotic had an earlier benefit in patients without a recent history of URTI compared to those with a recent history of URTI. Therefore, recent history of infections could have a modulatory effect on probiotic efficacy. Average number of months with reported use of URTI-related medication was 3.4-times lower in the probiotic group as compared to placebo ( = 0.016) during the intervention. Taken together, our present new data further support previous findings that DR7 probiotic had a beneficial effect on URTI.
我们之前报道了DR7对109名成年人上呼吸道感染（URTI）症状评分和频率的影响，这些成年人每天服用10个菌落形成单位（CFU），持续12周，但在该出版物中发现了一些局限性。因此，本研究重新分析了一些数据，旨在解决其中一些弱点，并提供了与安慰剂相比，URTI持续时间和URTI相关药物使用情况的新数据。我们的重新分析发现，服用益生菌显著降低了URTI患者天数和发烧的比例（均<0.05）。近期URTI病史是影响URTI症状持续时间和发烧的常见共同因素，而其他人口统计学和临床因素则没有影响。探索性分析表明，与有近期URTI病史的患者相比，益生菌对没有近期URTI病史的患者有更早的益处。因此，近期感染史可能对益生菌疗效有调节作用。在干预期间，益生菌组报告使用URTI相关药物的平均月数比安慰剂组低3.4倍（P = 0.016）。综上所述，我们目前的新数据进一步支持了之前的研究结果，即DR7益生菌对URTI有有益作用。
